The firm submitted non-clinical and clinical modules of its rolling BLA for DTX401 in August and has now submitted the chemistry, manufacturing, and controls module.
The firm is betting that adding the G-quadruplex stabilizer to the ADC will improve outcomes in HER2-low breast cancer patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback